Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits
Author(s) -
Robert J. Ignoffo,
Katherine K. Knapp,
Mitchell J. Barnett,
Sally Barbour,
Steve D’Amato,
Lew Iacovelli,
Jasen Knudsen,
Susannah E. Koontz,
Robert Mancini,
Ali McBride,
Dayna L. McCauley,
Patrick J. Medina,
Cindy L. O’Bryant,
Sarah L Scarpace,
Steve Stricker,
James A. Trovato
Publication year - 2016
Publication title -
journal of oncology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.555
H-Index - 60
eISSN - 1935-469X
pISSN - 1554-7477
DOI - 10.1200/jop.2015.008490
Subject(s) - medicine , clinical oncology , certification , oncology , radiation oncology , medline , family medicine , precision oncology , medical physics , cancer , political science , law , radiation therapy
With an aging US population, the number of patients who need cancer treatment will increase significantly by 2020. On the basis of a predicted shortage of oncology physicians, nonphysician health care practitioners will need to fill the shortfall in oncology patient visits, and nurse practitioners and physician assistants have already been identified for this purpose. This study proposes that appropriately trained oncology pharmacists can also contribute. The purpose of this study is to estimate the supply of Board of Pharmacy Specialties-certified oncology pharmacists (BCOPs) and their potential contribution to the care of patients with cancer through 2020.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom